Hereditary Angioedema
Customize your policy alerts
Sign up for Aetna Policy 0782 alerts
Get alerted when Policy 0782 changes without checking for updates manually.
Monitor payer policy activity
Defines Aetna's medical necessity, precertification, and coverage criteria for prophylactic and acute pharmacologic treatments for hereditary angioedema (HAE) for commercial medical plans and specifies site-of-care considerations for certain agents.
No material clinical or coverage changes in this revision.
Coverage Criteria for Hereditary Angioedema Therapies
Cinryze — Initial Approval (prophylaxis)
Covered when EITHER of the following diagnostic pathways is met and prescribed by or in consultation with an HAE specialist, and not used in combination with other prophylactic HAE medications:
AND one of: C1-INH antigenic level below laboratory lower limit OR normal antigenic level with C1-INH functional level <50% or below laboratory lower limit
AND one of: pathogenic mutation in F12, angiopoietin-1, plasminogen, KNG1, HS3ST6, or MYOF confirmed by genetic testing OR documented family history and refractory to a trial of high‑dose antihistamine (eg, cetirizine 40 mg/day or equivalent) for ≥1 month
Cinryze — Continuation of Therapy (prophylaxis)
Covered when ALL of the following are met:
Haegarda — Initial Approval (prophylaxis)
Covered when EITHER of the following diagnostic pathways is met and prescribed by or in consultation with an HAE specialist, and not used in combination with other prophylactic HAE medications:
Same laboratory criteria as other prophylactic agents: C1-INH antigenic level below lab lower limit OR normal antigenic with functional C1-INH <50% or below lab lower limit
Same genetic or family-history + antihistamine‑refractory criteria as Cinryze (F12, ANGPT1, plasminogen, KNG1, HS3ST6, MYOF mutation OR documented family history and refractory to ≥1 month high‑dose antihistamine)
Haegarda — Continuation of Therapy (prophylaxis)
Covered when ALL of the following are met:
Takhzyro — Initial Approval (prophylaxis)
Covered when EITHER of the following diagnostic pathways is met and prescribed by or in consultation with an HAE specialist, and not used in combination with other prophylactic HAE medications:
Same laboratory criteria as other prophylactic agents
AND one of: pathogenic mutation in F12, angiopoietin-1, plasminogen, KNG1, HS3ST6, or MYOF confirmed by genetic testing OR documented family history and refractory to ≥1 month trial of high‑dose antihistamine (eg, cetirizine 40 mg/day or equivalent)
Takhzyro — Continuation of Therapy (prophylaxis)
Covered when ALL of the following are met:
Berinert — Initial Approval (short-term preprocedural prophylaxis)
Covered for short-term preprocedural prophylaxis when prescribed by or in consultation with an HAE specialist and EITHER diagnostic pathway is met:
Same laboratory criteria as prophylactic agents
AND one of: specified gene mutation confirmed by genetic testing OR documented family history and refractory to ≥1 month high‑dose antihistamine trial
Berinert — Initial Approval (acute attacks)
Covered for treatment of acute HAE attacks when prescribed by or in consultation with an HAE specialist, not used in combination with other acute agents, and EITHER diagnostic pathway is met:
Same laboratory criteria as above
AND one of: pathogenic mutation in F12, angiopoietin-1, plasminogen, KNG1, HS3ST6, or MYOF OR documented family history and refractory to ≥1 month high‑dose antihistamine
Berinert — Continuation of Therapy (acute attacks)
Covered when ALL of the following are met:
Kalbitor — Initial Approval (acute attacks)
Covered for treatment of acute HAE attacks when prescribed by or in consultation with an HAE specialist, not used in combination with other acute agents, and EITHER diagnostic pathway is met:
Same laboratory criteria
AND one of: specified gene mutation confirmed by genetic testing OR documented family history and refractory to ≥1 month high‑dose antihistamine
Kalbitor — Continuation of Therapy (acute attacks)
Covered when ALL of the following are met:
Ruconest — Initial Approval and Continuation (acute attacks)
Covered for treatment of acute HAE attacks when prescribed by or in consultation with an HAE specialist, not used in combination with other acute agents, and diagnostic criteria mirrored to other acute agents:
AND one of: specified gene mutation confirmed by genetic testing OR documented family history and refractory to ≥1 month high‑dose antihistamine
Icatibant — Initial Approval and Continuation (acute attacks)
Covered for treatment of acute HAE attacks when prescribed by or in consultation with an HAE specialist, not used in combination with other acute agents, and diagnostic criteria are met:
AND one of: specified gene mutation confirmed by genetic testing OR documented family history and refractory to ≥1 month high‑dose antihistamine
Medication dosing and administration
Dosing and administration recommendations (per manufacturers) — implied coverage when clinical policy criteria are met
SC administration; intended for healthcare provider but may be self‑administered by trained persons.
IV only; trained persons may self‑administer upon recognition of an HAE attack.
Administer only by a healthcare professional with capability to manage anaphylaxis and HAE.
IV only; trained persons may self‑administer upon recognition of an HAE attack.
May be self‑administered by trained persons.
Experimental and investigational determinations
Aetna's experimental and investigational determinations (may lead to coverage denial for these uses)
Supports denial risk for combination prophylactic therapy.
May be denied for these indications.
May be denied for these indications.
May be denied for these indications.
May be denied for these indications.
May be denied for these indications.
Cinryze (C1-INH) prophylaxis
Covered when product-specific FDA indications and supporting clinical documentation are met
FDA approval and trial data support reduced attack rate and days of swelling
Haegarda (subcutaneous C1-INH) prophylaxis
Covered when product-specific FDA indications and supporting clinical documentation are met
Subcutaneous route allows at‑home self‑injection after training; common adverse reactions include injection site reactions, hypersensitivity, nasopharyngitis and dizziness.
Takhzyro (lanadelumab) prophylaxis
Covered when product-specific FDA indications and supporting clinical documentation are met
Dosing regimens include 300 mg q2w with higher attack‑free rates; common adverse reactions include injection site reactions and dizziness.
FDA indications and trial-based efficacy/safety summaries
Summaries of FDA-approved indications and key clinical trial findings for prophylactic and acute HAE treatments
FDA label expanded to include pediatric patients ≥2 years based on HELP and SPRING data.
Self‑administration permitted with training; safety warnings include hypersensitivity and thromboembolic events.
Patients treated for laryngeal attacks should seek immediate medical attention after treatment.
Carries a boxed warning for anaphylaxis; must be administered where anaphylaxis can be managed.
Evidence supporting acute HAE therapies
Clinical evidence supporting acute use:
Kalbitor carries anaphylaxis risk; administer in setting with anaphylaxis management available.
Supports role of kallikrein inhibition in HAE pathophysiology.
Limitation of use: effectiveness not established for laryngeal attacks; repeat IgE testing annually or after 10 treatments.
Aetna covers hereditary angioedema (HAE) agents only for the specific prophylactic, short‑term preprocedural prophylaxis, and acute‑attack indications described in this policy. All other indications not expressly listed are considered experimental and investigational and are subject to denial. Providers must document that requested use aligns with the diagnostic, prescriber specialty, and usage criteria in this policy (e.g., specialist prescribing or consultation) before coverage will be approved.
Certain ICD‑10 diagnoses are explicitly noted as not covered when used to support HAE therapy requests in this policy. Examples called out in the coding section include A41.9 (sepsis, unspecified) and a range of cerebrovascular and myocardial infarction codes (e.g., transient ischemic attack and stroke codes G45.x; I21.x–I22.x). These ICD‑10 examples are not an all‑inclusive list but illustrate non‑covered acute systemic or vascular indications outside the approved HAE uses.
Human C1‑INH products and other HAE agents should not be used in patients with a reported hypersensitivity to the product or any component. Haegarda carries a labelled warning for severe hypersensitivity and is contraindicated in individuals with prior life‑threatening hypersensitivity to C1‑INH. Plasma‑derived products (e.g., Berinert, Haegarda) also carry theoretical infectious‑agent transmission risks and have specific labeled warnings regarding thromboembolic events.
Berinert is not established for routine long‑term prophylaxis. Aetna considers Berinert experimental and investigational for prophylactic use except for short‑term preprocedural prophylaxis when the policy’s specific criteria for that indication are met.
Ruconest is approved for treatment of acute HAE attacks, but the label includes a limitation of use: effectiveness has not been established for HAE patients with laryngeal attacks. This limitation should be considered when selecting acute‑attack therapy and documenting treatment rationale.
Per Aetna brand‑selection guidance, use of the higher‑cost product Berinert for acute HAE attacks is considered medically necessary only after a one‑month trial of the lower‑cost equivalent Ruconest unless there is documented contraindication, intolerance, or ineffective response to Ruconest.
Concomitant use of multiple prophylactic agents (e.g., Cinryze, Haegarda, Takhzyro) or combinations of acute agents is considered experimental and investigational. Aetna may deny requests for uses or combinations that the policy specifically lists as investigational because effectiveness for those uses has not been established.
For HAE with normal C1‑INH (formerly HAE type III), there are no randomized controlled trials establishing efficacy of the available therapies. Evidence is limited to case reports and small series, and treatment recommendations cannot be firmly established; therefore use of HAE agents in this population should be considered with caution and may be unsupported by high‑quality trial data.
Coding and Dosing References
| 86160 | Complement; antigen, each component [C4 level] |
| 96365-96368 | Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug) |
| 96374-96376 | Therapeutic, prophylactic, or diagnostic injection; intravenous push |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
| 96379 | Unlisted therapeutic, prophylactic, or diagnostic IV or intra-arterial injection or infusion |
| J0598 | Injection, C1 esterase inhibitor (human) cinryze, 10 units |
| J0599 | Injection, C-1 esterase inhibitor (human), (haegarda), 10 units |
| J0593 | Injection, lanadelumab-flyo, 1 mg |
| J0597 | Injection, C-1 esterase inhibitor (human), berinert, 10 units |
| J0596 | Injection, c1 esterase inhibitor (recombinant), ruconest, 10 units |
Provider Actions, Prior Authorization, and Safety Requirements
Precertification Required
Precertification of hereditary angioedema (HAE) agents is required for all Aetna participating providers and members in applicable plan designs. For precertification of HAE agents, call (866) 752-7021 or fax (888) 267-3277. Statement of Medical Necessity (SMN) precertification forms are available via Aetna Specialty Pharmacy Precertification resources. Failure to obtain required precertification may result in denial of the request.
- Precertification contact: (866) 752-7021; fax (888) 267-3277
- SMN precertification forms: Specialty Pharmacy Precertification
Brand Selection and Step to Lower-Cost Alternative Before Berinert
Berinert is a more costly acute HAE agent compared with alternatives (e.g., Ruconest). Per Aetna brand-selection policy, Berinert is considered medically necessary for acute attacks only when the member has a documented contraindication, intolerance, or ineffective response to the available equivalent lower-cost alternative (one-month trial): Ruconest. Requests for Berinert should include documentation supporting that Ruconest was tried and failed, was not tolerated, or is contraindicated.
- Berinert considered medically necessary only after contraindication/intolerance/ineffective response to Ruconest (one-month trial)
- Document trial dates, dosing, response, and reason Ruconest not appropriate
Documentation of Dosing, Route, and Patient Weight
Providers must document key clinical and dosing information with any request: the specific product requested (brand), indication, dosing (dose and dose per kg when applicable), route of administration, frequency, and the patient’s weight (for weight-based dosing). For Berinert and Ruconest, include the calculated IU dose based on patient weight and any prior doses given.
- Document patient weight and show dose calculation (e.g., Berinert 20 IU/kg; Ruconest 50 U/kg, max 4200 U)
- Specify route (IV vs SC), dosing frequency, and actual administered dose(s) with dates
Prescriber Specialty Documentation Requirement
Prescriber specialty: prophylactic C1-INH agents (e.g., Cinryze, Haegarda) should be prescribed by or in consultation with a clinician who specializes in the management of HAE. Include specialty and consultation notes as applicable.
- Prescriber specialty or consult note required for prophylactic C1-INH requests
- Site-of-care utilization management may apply to certain products (e.g., Cinryze)
Requests for the More Costly Agent Berinert
For Berinert requests, include clinical documentation of the acute attack severity, prior treatments used during the attack (and response), and any rescue medication administered. For prophylactic or acute use, document contraindications or intolerance to lower-cost alternatives when claiming medical necessity for a more costly agent.
- Attack severity, timing, and treatment response (including rescue medications)
- If requesting Berinert without prior Ruconest trial, document contraindication/intolerance/clinical rationale
IgE Testing Prior to Ruconest
Before initiating Ruconest in patients who have not previously received it, providers should document IgE testing for rabbit epithelium (dander) to assess for potential hypersensitivity. Only patients with negative IgE testing should be treated with Ruconest. Repeat IgE testing annually or after every 10 treatments, whichever comes first.
- IgE antibody testing to rabbit epithelium required prior to first Ruconest dose
- Repeat testing: once a year or after 10 treatments, whichever occurs first
Concomitant Prophylactic Agent Use Is Experimental/Investigational
Concomitant use of multiple prophylactic HAE agents (e.g., Cinryze, Haegarda, Takhzyro) is considered experimental and investigational; such combinations are not supported by established evidence. Requests proposing combination prophylactic therapy should include rationale and supporting evidence but may be denied as investigational.
- Concomitant use of Cinryze, Haegarda, and/or Takhzyro considered experimental/investigational
- Provide evidence if combination therapy is being requested; expect higher denial risk
Kalbitor Administration Setting and Age Requirements
Kalbitor (ecallantide) carries a boxed warning for anaphylaxis and must be administered by a healthcare professional in a setting equipped to manage anaphylaxis. Document the administration setting and that appropriate medical support is available when requesting Kalbitor.
- Kalbitor administration must occur where anaphylaxis can be managed; document setting and clinician availability
- Age restriction: Kalbitor indicated for patients 12 years and older
Therapeutic Sequencing and Rationale for Prophylaxis
For prophylactic HAE therapies (Cinryze, Haegarda, Takhzyro), document prior therapy history (including androgens and antifibrinolytics), frequency and severity of attacks, and rationale for selecting prophylaxis over on-demand therapy. Note that therapeutic sequencing (androgens vs C1-INH products) and selection should be justified in the medical record.
- Document prior androgen or antifibrinolytic use and reasons for discontinuation or intolerance
- Provide attack frequency, prior ED visits/hospitalizations, laryngeal history, and quality-of-life impact to support prophylaxis
Background on Hereditary Angioedema
Background: Hereditary angioedema (HAE) is a rare, potentially life‑threatening genetic disorder caused by deficiency or dysfunction of C1 esterase inhibitor (C1‑INH) that results in recurrent, non‑urticarial angioedema episodes mediated primarily by bradykinin. Type I HAE (approximately 85% of cases) is characterized by low levels of C1‑INH, and Type II by dysfunctional C1‑INH. Management includes on‑demand treatment of acute attacks, short‑term preprocedural prophylaxis, and long‑term prophylaxis. Approved therapeutic classes include C1‑INH replacement (plasma‑derived and recombinant), plasma kallikrein inhibitors (e.g., lanadelumab), and bradykinin B2 receptor antagonists (e.g., icatibant).
Definitions and Diagnostic Criteria
Policy Revision History
Policy effective date established for hereditary angioedema clinical policy bulletin number 0782.
FDA approved Ruconest (recombinant C1 esterase inhibitor) for treatment of acute HAE attacks in adults and adolescents; policy references this approval and associated safety/testing recommendations.
FDA approved Berinert for pediatric patients (under 12 years) for treatment of HAE attacks; policy cites this pediatric approval and related safety information.
FDA approved Haegarda for prevention of HAE attacks in patients 6 years of age and older; policy incorporates the product indication and precautions.
FDA approved Takhzyro (lanadelumab-flyo) for prophylaxis to prevent HAE attacks in patients 12 years and older; policy includes trial efficacy data and prophylaxis criteria.
Cinryze received supplemental FDA approval to include children 6 years and older for routine prophylaxis; policy reflects this approval and dosing considerations.
FDA expanded Takhzyro label to include prophylaxis in pediatric patients 2 years and older; policy notes the February 2023 label expansion and corresponding prior authorization implications.
Clinical policy bulletin 0782 was last reviewed on 2023-09-11; effective date remains 2009-04-10 and next review was scheduled for 2024-06-27.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.